Trial Profile
A Randomized, Multicenter, International, Open-Label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MT naïve Subjects With Active Psoriatic Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Methotrexate
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms RESPOND
- Sponsors Integrated Therapeutics Group; Merck Sharp & Dohme; Schering-Plough
- 15 Jun 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
- 12 Oct 2011 Results published in full in the Annals of the Rheumatic Diseases.
- 21 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology.